Nakanishi Xin Net Worth

Nakanishi Xin biography

Dr. Nakanishi Xin Ph.D. serves as Director of the Company. She has served as the Chief Executive Officer of Shanghai Pharma Biotherapeutics USA Inc., a subsidiary of and Shanghai Pharmaceutical (USA) Inc. (SPH USA), since July 2018. Dr. Nakanishi previously served as a venture partner at Yuansheng BioVenture from 2017-2018, and was CEO and founder of Sunvita Therapeutics, LLC from 2009-2018 a company that provided cross border business development for various U.S. and Chinese biopharmaceutical companies. She was also the Director of Biology at Phenomix Inc., a senior scientist at Pfizer, and a group leader at Immusol Inc. Dr. Nakanishi holds a B.A. in Virology from Wuhan University and a Ph.D. in Biochemistry from the University of Kansas. Dr. Nakanishi’s extensive experience in the life science and pharmaceutical industries contributed to the board of directors’ conclusion that she should serve as a director of the Company.

How old is Nakanishi Xin?

Nakanishi Xin is 58, he's been the Director of Oncternal Therapeutics since 2019. There are 8 older and 6 younger executives at Oncternal Therapeutics. The oldest executive at Oncternal Therapeutics, Inc. is Michael Carter, 82, who is the Independent Director.

What's Nakanishi Xin's mailing address?

Xin's mailing address filed with the SEC is 12230 EL CAMINO REAL, SUITE 230, , SAN DIEGO, CA, 92130.

Insiders trading at Oncternal Therapeutics

Over the last 5 years, insiders at Oncternal Therapeutics have traded over $26,287 worth of Oncternal Therapeutics stock and bought 1,526,610 units worth $3,062,129 . The most active insiders traders include Pharmaceutical (Usa) Inc.Sh..., Charles Theuer e Robert James Wills. On average, Oncternal Therapeutics executives and independent directors trade stock every 68 days with the average trade being worth of $302,970. The most recent stock trade was executed by Robert James Wills on 8 April 2024, trading 3,086 units of ONCT stock currently worth $27,651.

What does Oncternal Therapeutics do?

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1. The company is headquartered in San Diego, California.

Oncternal Therapeutics executives and stock owners

Oncternal Therapeutics executives and other stock owners filed with the SEC include:

• James Breitmeyer,
  President, Chief Executive Officer, Director
• Dr. James B. Breitmeyer,
  Pres, CEO & Director
• Frank Hsu,
  Chief Medical Officer
• Dr. Gunnar F. Kaufmann Ph.D.,
  Chief Scientific Officer
• Charles Theuer,
  Independent Director
• William LaRue,
  Independent Director
• Daniel Kisner,
  Independent Director
• Michael Carter,
  Independent Director
• Nakanishi Xin,
  Director
• Robert Wills,
  Director
• Man Cho,
  Director
• Igor Bilinsky,
  Chief Business Officer
• Gunnar Kaufmann,
  Chief Scientific Officer
• Richard Vincent,
  Chief Financial Officer, Treasurer, Secretary
• David Hale,
  Independent Chairman of the board
• Dr. Steven Hamburger Ph.D.,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Salim Yazji,
  Chief Medical Officer
• Pablo Urbaneja,
  Sr. VP of Corp. Devel.
• Chase C. Leavitt,
  Gen. Counsel
• Dr. Rajesh Krishnan Ph.D.,
  Chief Technology Officer
• Rajesh Krishnan,
  CTO/CSO
• Pharmaceutical (Usa) Inc.Sh...,
  
• Yanjun Liu,
  Director
• Hazel M Aker,
  Legal Counsel
• Pharmaceutical (Usa) Inc. S...,
  10% owner
• Rosemary Mazanet,
  
• Jinzhu Ph D Chen,
  Director
• Chase C. Leavitt,
  General Counsel/Secretary
• Salim Yazji,
  Chief Medical Officer
• Jill De Simone,